EUCTR2021-002641-15-NL进行中（未招募）1 期
SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment - SPLASH
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 390
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Patients are eligible to be included in the study only if all of the following criteria apply:
- •1. Male aged 18 years or older.
- •2. Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate.
- •3. Ineligible or averse to chemotherapeutic treatment options.
- •4. Patients must have progressive mCRPC at the time of consent based on at least 1 of the following criteria:
- •a. Serum/plasma PSA progression defined as increase in PSA greater than 25% and >2 ng/mL above nadir, confirmed by progression at 2 time points at least 3 weeks apart.
- •b. Soft-tissue progression defined as an increase =20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or a new lesion.
- •c. Progression of bone disease: defined as appearance of two or more new lesions by bone scan.
- •5. Progression on previous treatment with one ARAT (abiraterone or enzalutamide or darolutamide or apalutamide) in either the CSPC or CRPC setting.
- •6. PSMA-PET scan (i.e., 68Ga-PSMA-11 or 18F-DCFPyL) positive as determined by the sponsor's central reader.
- •7. Castrate circulating testosterone levels (<1.7 nmol/L or <50 ng/dL).
- •8. Adequate organ function, independent of transfusion:
- •a. Bone marrow reserve:
- •i. White blood cell (WBC) count =2.5 × 109/L OR absolute neutrophil count (ANC) =1.5 × 109/L.
- •ii. Platelets =100 × 109/L.
- •iii. Hemoglobin =8 g/dL.
- •b. Liver function:
- •i. Total bilirubin =1.5 × institutional upper limit of normal (ULN). For patients with known Gilbert’s syndrome, =3 × ULN is permitted.
- •ii. ALT or AST =3.0× ULN.
- •c. Renal function:
- •i. Serum/plasma creatinine =1.5 × ULN or creatinine clearance =50 mL/min based on Cockcroft-Gault formula. (for patients in France, serum/plasma creatinine =1.5 × ULN or CrCl =60 mL/min based on Cockcroft-Gault formula).
- •d. Albumin =30 g/L.
- •9. Human immunodeficiency virus-infected patients who are healthy and have a low risk of acquired immunodeficiency syndrome-related outcomes are included in this trial.
- •10. For patients who have partners who are pregnant or of childbearing potential a condom is required along with a highly effective contraceptive method during the study and for 6 months after last study drug administration. Such methods deemed highly effective include
- •a) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation
- •b) progestogen-only hormonal contraception associated with inhibition of ovulation
- •c) intrauterine device (IUD), d) intrauterine hormone-releasing system (IUS)
- •e) bilateral tubal occlusion
- •f) vasectomy
- •g) sexual abstinence.
- •11. Willing to initiate ARAT therapy (either enzalutamide or abiraterone), pre-specified by investigator, if randomized to Treatment Arm B.
- •12. ECOG performance status 0 to 1.
- •13. Willing and able to comply with all study requirements and treatments (including 177Lu-PNT2002) as well as the timing and nature of required assessments.
- •14. Signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 117
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 273
排除标准
- •Patients are excluded from the study if any of the following criteria apply:
- •1. If noted in pathology report, prostate cancer with known significant (>10% present in cells) sarcomatoid or spindle cell or neuroendocrine components. Any small cell component in the cancer should result in exclusion.
- •2. Prior treatment for prostate cancer =28 days prior to randomization, with the exclusion of first line local external beam, ARAT, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist therapy, or non-radioactive bone-targeted agents.
- •3. Any prior cytotoxic chemotherapy for CRPC (e.g., cabazitaxel or docetaxel); chemotherapy for hormone-sensitive prostate cancer (HSPC) is allowed if the last dose was administered >1 year prior to consent.
- •4. Prior treatment with systemic radionuclides (e.g. radium-223, rhenium-186, strontium-89).
- •5. Prior immuno-therapy, except for sipuleucel-T.
- •6. Prior PSMA-targeted radioligand therapy, e.g., Lu-177-PSMA-617, I 131-1095.
- •7. Prior poly ADP ribose polymerase (PARP) inhibitor for prostate cancer.
- •8. Patients who progressed on 2 or more lines of ARATs.
- •9. Patients receiving bone-targeted therapy (e.g. denosumab, zoledronic acid) are excluded if they are not on stable doses for at least 4 weeks prior to randomization.
- •10. Administration of an investigational agent =60 days or 5 half-lives, whichever is shorter, prior to randomization.
- •11. Major surgery =30 days prior to randomization.
- •12. Estimated life expectancy <6 months as assessed by the principal investigator.
- •13. Presence of liver metastases >1 cm on abdominal imaging.
- •14. A superscan on bone scan defined as a bone scan that demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint genitourinary tract activity71.
- •15. Dose escalation or initiation of opioids for cancer-related pain =30 days prior to consent up to and including randomization.
- •16. Known presence of central nervous system metastases.
- •17. Contraindications to the use of planned ARAT therapy, [Ga-68]-PSMA-11, [F-18]-DCFPyL or [Lu-177]-PNT2002 therapy, including but not limited to the following:
- •a. Hypersensitivity to [Ga-68]-PSMA-11, [F-18]-DCFPyL or [Lu-177]-PNT2002 excipients (Diethylenetriaminepentaacetic acid (DTPA), Sodium ascorbate, L-ascorbic acid, Sodium gentisate, HCl, Sodium
- •b. Recent myocardial infarction or arterial thrombotic events (in the past 6 months) or unstable angina (in the past 3 months), bradycardia or left ventricular ejection fraction measurement of < 50%
- •c. History of seizures in patients planned to receive enzalutamide
- •18. Active malignancy other than low-grade non-muscle-invasive bladder cancer and non-melanoma skin cancer.
- •19. Concurrent illness that may jeopardize the patient’s ability to undergo study procedures.
- •20. Serious psychological, familial, sociological, or geographical condition that might hamper compliance with the study protocol and follow-up schedule. Patients that travel need to be capable of repeated visits even if they are on the control arm.
- •21. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
- •22. Concurrent serious (as determined by the investigator) medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, unstable ischemia, uncontrolled symptomatic arrhythmia, history of congenital prolonged QT syndrome, uncontrolled infection, known activ
研究者
相似试验
进行中（未招募）
1 期
To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPCEUCTR2021-002641-15-SEPoint BioPharma Inc.390
招募中
3 期
SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu- PNT2002 PSMA Therapy After Second-line Hormonal Treatment10027655prostate cancerNL-OMON54469POINT BioPharma,30
尚未招募
2 期
Targeted a-Therapy in Prostate CancerProstate cancer.Malignant neoplasm of prostateIRCT20210612051548N1Boushehr University of Medical Sciences10
进行中（未招募）
1 期
Phase 2 Study in 1L HNSCC of IT MK-1454 / MK-3475 IV vs MK-3475 IVPatients with metastatic or unresectable, recurrent HNSCCEUCTR2019-003060-42-NOMerck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc200
进行中（未招募）
1 期
Phase 2 Study in 1L HNSCC of IT MK-1454 / MK-3475 IV vs MK-3475 IVPatients with metastatic or unresectable, recurrent HNSCCEUCTR2019-003060-42-ESMerck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc18